High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
Introduction: Third-generation EGFR tyrosine kinase inhibitors (TKIs) have improved outcomes in EGFR-mutant non–small cell lung cancer (NSCLC), but resistance occurs, especially in patients with Brain metastases (BMs). Antiangiogenic therapy may enhance CNS drug delivery and EGFR-TKI efficacy. We e...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-11-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523325002311 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849233838533771264 |
|---|---|
| author | Yin Pan Meichen Li Mingjie Yu Jing Chen Hui Yu Kaijing Liu Likun Chen |
| author_facet | Yin Pan Meichen Li Mingjie Yu Jing Chen Hui Yu Kaijing Liu Likun Chen |
| author_sort | Yin Pan |
| collection | DOAJ |
| description | Introduction: Third-generation EGFR tyrosine kinase inhibitors (TKIs) have improved outcomes in EGFR-mutant non–small cell lung cancer (NSCLC), but resistance occurs, especially in patients with Brain metastases (BMs). Antiangiogenic therapy may enhance CNS drug delivery and EGFR-TKI efficacy. We evaluated the efficacy of high-dose furmonertinib plus bevacizumab in patients with BMs after third-generation EGFR-TKI failure. Methods: We conducted a single-center retrospective study in EGFR-mutant NSCLC patients with BMs (leptomeningeal and/or parenchymal) who had progressed after ≥1 third-generation EGFR-TKI. Patients received furmonertinib 160 mg daily plus bevacizumab 7.5 mg/kg every 3 weeks until progression or unacceptable toxicity. Primary endpoints were intracranial and overall progression-free survival (iPFS, PFS); secondary endpoints were intracranial and systemic objective response rates (iORR, ORR) and safety. Results: Among the 78 enrolled patients (median follow-up: 11.8 months), median iPFS and PFS were 7.2 months (95 % CI: 5.6–10.5) and 5.85 months (95 % CI: 4.6–7.4), respectively. The iORR was 37.1 %, and ORR was 28.6 %. OS data remain immature at the time of analysis. In patients with both parenchymal and leptomeningeal metastases (n = 47), median iPFS was 7.63 months (95 % CI: 5.0–10.8), and median PFS was 5.7 months (95 % CI: 4.5–10.0); iORR and ORR were 40.5 % and 34.2 %, respectively. In the parenchymal-only subgroup (n = 31), median iPFS and PFS were 7.20 months (95 % CI: 5.5–NR) and 6.4 months (95 % CI: 4.4–11.3), iORR and ORR were 32 % and 20 %. In multivariate analysis, EGFR exon 19 deletion was independently associated with prolonged iPFS (HR = 0.32, P = 0.011) and PFS (HR = 0.47, P = 0.047). CNS radiotherapy administered during treatment also emerged as an independent prognostic factor for both iPFS (HR = 0.34, P = 0.022) and PFS (HR = 0.40, P = 0.018). Conclusion: In this retrospective study, high-dose furmonertinib combined with bevacizumab demonstrated favorable intracranial and systemic activity with an acceptable safety profile in EGFR-mutant NSCLC patients with CNS metastases after resistance to third-generation EGFR-TKIs. These findings provide preliminary evidence supporting the potential clinical benefit of this chemotherapy-sparing strategy. Importantly, these findings warrant further validation in biomarker-stratified prospective trials to guide patient selection and optimize treatment outcomes. |
| format | Article |
| id | doaj-art-4b3bccc1d2ca4c7d861546fa3d4a62d1 |
| institution | Kabale University |
| issn | 1936-5233 |
| language | English |
| publishDate | 2025-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj-art-4b3bccc1d2ca4c7d861546fa3d4a62d12025-08-20T04:03:22ZengElsevierTranslational Oncology1936-52332025-11-016110250010.1016/j.tranon.2025.102500High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective studyYin Pan0Meichen Li1Mingjie Yu2Jing Chen3Hui Yu4Kaijing Liu5Likun Chen6Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR ChinaDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR ChinaDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR ChinaDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR ChinaDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR ChinaDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR ChinaCorresponding author at: Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng E Rd, Yuexiu District, Guangzhou, 510060, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR ChinaIntroduction: Third-generation EGFR tyrosine kinase inhibitors (TKIs) have improved outcomes in EGFR-mutant non–small cell lung cancer (NSCLC), but resistance occurs, especially in patients with Brain metastases (BMs). Antiangiogenic therapy may enhance CNS drug delivery and EGFR-TKI efficacy. We evaluated the efficacy of high-dose furmonertinib plus bevacizumab in patients with BMs after third-generation EGFR-TKI failure. Methods: We conducted a single-center retrospective study in EGFR-mutant NSCLC patients with BMs (leptomeningeal and/or parenchymal) who had progressed after ≥1 third-generation EGFR-TKI. Patients received furmonertinib 160 mg daily plus bevacizumab 7.5 mg/kg every 3 weeks until progression or unacceptable toxicity. Primary endpoints were intracranial and overall progression-free survival (iPFS, PFS); secondary endpoints were intracranial and systemic objective response rates (iORR, ORR) and safety. Results: Among the 78 enrolled patients (median follow-up: 11.8 months), median iPFS and PFS were 7.2 months (95 % CI: 5.6–10.5) and 5.85 months (95 % CI: 4.6–7.4), respectively. The iORR was 37.1 %, and ORR was 28.6 %. OS data remain immature at the time of analysis. In patients with both parenchymal and leptomeningeal metastases (n = 47), median iPFS was 7.63 months (95 % CI: 5.0–10.8), and median PFS was 5.7 months (95 % CI: 4.5–10.0); iORR and ORR were 40.5 % and 34.2 %, respectively. In the parenchymal-only subgroup (n = 31), median iPFS and PFS were 7.20 months (95 % CI: 5.5–NR) and 6.4 months (95 % CI: 4.4–11.3), iORR and ORR were 32 % and 20 %. In multivariate analysis, EGFR exon 19 deletion was independently associated with prolonged iPFS (HR = 0.32, P = 0.011) and PFS (HR = 0.47, P = 0.047). CNS radiotherapy administered during treatment also emerged as an independent prognostic factor for both iPFS (HR = 0.34, P = 0.022) and PFS (HR = 0.40, P = 0.018). Conclusion: In this retrospective study, high-dose furmonertinib combined with bevacizumab demonstrated favorable intracranial and systemic activity with an acceptable safety profile in EGFR-mutant NSCLC patients with CNS metastases after resistance to third-generation EGFR-TKIs. These findings provide preliminary evidence supporting the potential clinical benefit of this chemotherapy-sparing strategy. Importantly, these findings warrant further validation in biomarker-stratified prospective trials to guide patient selection and optimize treatment outcomes.http://www.sciencedirect.com/science/article/pii/S1936523325002311FurmonertinibEGFR-TKI resistanceBrain MetastasesEGFR mutation |
| spellingShingle | Yin Pan Meichen Li Mingjie Yu Jing Chen Hui Yu Kaijing Liu Likun Chen High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study Translational Oncology Furmonertinib EGFR-TKI resistance Brain Metastases EGFR mutation |
| title | High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study |
| title_full | High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study |
| title_fullStr | High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study |
| title_full_unstemmed | High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study |
| title_short | High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study |
| title_sort | high dose furmonertinib plus bevacizumab in egfr mutant non small cell lung cancer with brain metastases after resistance to third generation egfr tkis a retrospective study |
| topic | Furmonertinib EGFR-TKI resistance Brain Metastases EGFR mutation |
| url | http://www.sciencedirect.com/science/article/pii/S1936523325002311 |
| work_keys_str_mv | AT yinpan highdosefurmonertinibplusbevacizumabinegfrmutantnonsmallcelllungcancerwithbrainmetastasesafterresistancetothirdgenerationegfrtkisaretrospectivestudy AT meichenli highdosefurmonertinibplusbevacizumabinegfrmutantnonsmallcelllungcancerwithbrainmetastasesafterresistancetothirdgenerationegfrtkisaretrospectivestudy AT mingjieyu highdosefurmonertinibplusbevacizumabinegfrmutantnonsmallcelllungcancerwithbrainmetastasesafterresistancetothirdgenerationegfrtkisaretrospectivestudy AT jingchen highdosefurmonertinibplusbevacizumabinegfrmutantnonsmallcelllungcancerwithbrainmetastasesafterresistancetothirdgenerationegfrtkisaretrospectivestudy AT huiyu highdosefurmonertinibplusbevacizumabinegfrmutantnonsmallcelllungcancerwithbrainmetastasesafterresistancetothirdgenerationegfrtkisaretrospectivestudy AT kaijingliu highdosefurmonertinibplusbevacizumabinegfrmutantnonsmallcelllungcancerwithbrainmetastasesafterresistancetothirdgenerationegfrtkisaretrospectivestudy AT likunchen highdosefurmonertinibplusbevacizumabinegfrmutantnonsmallcelllungcancerwithbrainmetastasesafterresistancetothirdgenerationegfrtkisaretrospectivestudy |